Tenax Therapeutics Crecimiento futuro

Future controles de criterios 0/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Tenax Therapeutics de 53.5% y 61% respectivamente, mientras que el BPA crecerá en un 67.1% al año.

Información clave

53.5%

Tasa de crecimiento de los beneficios

67.1%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	24.5%
Tasa de crecimiento de los ingresos	61.0%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	09 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Tenax to evaluate strategic alternatives including a sale or a merger, shares rise ~7%

Sep 15

Are Insiders Selling Tenax Therapeutics, Inc. (NASDAQ:TENX) Stock?

Jan 20

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:TENX - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	4	-16	N/A	N/A	2
12/31/2025	N/A	-18	N/A	N/A	2
12/31/2024	N/A	-16	N/A	N/A	2
12/31/2023	N/A	-8	-6	-6	N/A
9/30/2023	N/A	-7	-7	-7	N/A
6/30/2023	N/A	-8	-8	-8	N/A
3/31/2023	N/A	-10	-11	-11	N/A
12/31/2022	N/A	-11	-11	-11	N/A
9/30/2022	N/A	-12	-12	-12	N/A
6/30/2022	N/A	-13	-12	-12	N/A
3/31/2022	N/A	-11	-11	-11	N/A
12/31/2021	N/A	-32	-11	-11	N/A
9/30/2021	N/A	-32	-10	-10	N/A
6/30/2021	N/A	-31	-9	-9	N/A
3/31/2021	N/A	-31	-10	-10	N/A
12/31/2020	N/A	-10	-9	-9	N/A
9/30/2020	N/A	-10	-9	-9	N/A
6/30/2020	N/A	-10	-8	-8	N/A
3/31/2020	N/A	-9	-8	-8	N/A
12/31/2019	N/A	-8	-8	-8	N/A
9/30/2019	N/A	-15	-7	-7	N/A
6/30/2019	N/A	-14	-7	-7	N/A
3/31/2019	N/A	-15	-6	-6	N/A
12/31/2018	N/A	-14	-6	-5	N/A
9/30/2018	N/A	-6	-6	-6	N/A
6/30/2018	N/A	-6	-5	-5	N/A
3/31/2018	N/A	-7	-10	-10	N/A
12/31/2017	N/A	-9	-12	-12	N/A
9/30/2017	N/A	-37	N/A	-14	N/A
6/30/2017	N/A	-40	N/A	-17	N/A
3/31/2017	N/A	-42	N/A	-17	N/A
12/31/2016	N/A	-44	N/A	-16	N/A
9/30/2016	0	-19	N/A	-18	N/A
6/30/2016	0	-17	N/A	-17	N/A
3/31/2016	N/A	-18	N/A	-14	N/A
12/31/2015	N/A	-15	N/A	-13	N/A
10/31/2015	0	-14	N/A	-11	N/A
7/31/2015	0	-15	N/A	-12	N/A
4/30/2015	0	-14	N/A	-10	N/A
1/31/2015	0	-20	N/A	-11	N/A
10/31/2014	0	-21	N/A	-11	N/A
7/31/2014	0	-23	N/A	-10	N/A
4/30/2014	0	-25	N/A	-9	N/A
1/31/2014	1	-18	N/A	-8	N/A
10/31/2013	1	-16	N/A	-6	N/A
7/31/2013	1	-11	N/A	-5	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que TENX siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que TENX siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que TENX siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que TENX no tenga ingresos el año que viene.

Ingresos de alto crecimiento: Se prevé que TENX no tenga ingresos el año que viene.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de TENX se prevé que sea elevada dentro de 3 años.

Tenax Therapeutics Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Forecast to breakeven in 2026

Price target increased by 16% to US$110

Forecast to breakeven in 2023

Price target decreased to US$4.00

Forecast to breakeven in 2022

Price target increased to US$4.75

Recent updates

Tenax Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

New minor risk - Profitability

Tenax Therapeutics Enrolls First Patient in Phase 3 Level Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in PH-HFpEF Patients

Tenax Therapeutics, Inc. Appoints Lawrence R. Hoffman as Principal Financial Officer and Principal Accounting Officer

Tenax Therapeutics Receives Non-Compliance Notice from Nasdaq

Forecast to breakeven in 2026

Tenax Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $36 million.

Tenax Therapeutics, Inc. Appoints Javed Butler to its PH-HFpEF Scientific Advisory Board

Tenax Therapeutics, Inc. Announces FDA Clearance of IND for TNX-103 for the Treatment of Pulmonary Hypertension with Heart Failure

New major risk - Share price stability

The Nasdaq Stock Market LLC Grants Tenax Therapeutics's Request for an Extension Through March 25, 2024 to Evidence Compliance with the $1.00 Per Share Requirement for Continued Inclusion on the Nasdaq Capital Market

Tenax Therapeutics Issues U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Tenax Therapeutics, Inc. Receives a Notice of Allowance from the United States Patent and Trademark Office for its Patent Application

Price target increased by 16% to US$110

Tenax Receives Notice of Allowance for U.S. Patent Application Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)

High number of new and inexperienced directors

Tenax Therapeutics, Inc. Announces the Presentation of Positive Data from a Study of PH-HFpEF Patients Being Treated with Oral Levosimendan

Tenax to evaluate strategic alternatives including a sale or a merger, shares rise ~7%

Tenax Therapeutics, Inc. Receives Formal Notice That the Nasdaq Stock Market LLC

Forecast to breakeven in 2023

Tenax Therapeutics, Inc. Announces Resignation of Executives

Price target decreased to US$4.00

Tenax Therapeutics, Inc. Announces Successful Comparative Pharmacokinetic Study of TNX-201 for the Treatment of Pulmonary Arterial Hypertension

Tenax Therapeutics, Inc. announced that it expects to receive $8 million in funding from Armistice Capital LLC

High number of new and inexperienced directors

Tenax Therapeutics, Inc. Appoints Robyn Hunter to the Board of Directors

Tenax Therapeutics Provides Update on TNX-102, TNX-103 and TNX-201 Clinical Programs

High number of new and inexperienced directors

Forecast to breakeven in 2022

Price target increased to US$4.75

Independent Director James Mitchum has left the company

Tenax Therapeutics, Inc. Announces New Publication Highlighting Novel Levosimendan Mechanism of Action in Pulmonary Hypertension Patients with Heart Failure and Preserved Ejection Fraction

High number of new directors

CEO & Director Anthony DiTonno has left the company

Independent Director Chris Rallis has left the company

Independent Director Gregory Pepin has left the company

Independent Chairman Ronald Blanck has left the company

Price target increased to US$4.75

Tenax Therapeutics, Inc. Expands Board of Directors

New 90-day high: US$2.78

Tenax Therapeutics, Inc. (NasdaqCM:TENX) acquired PH Precision Med Inc. for $21.6 million.

Are Insiders Selling Tenax Therapeutics, Inc. (NASDAQ:TENX) Stock?

New 90-day high: US$2.36

New 90-day high: US$1.98

Tenax Therapeutics, Inc. Announces Presentation of 24-Hour HELP Study Results at the American Heart Association Scientific Sessions 2020

New 90-day low: US$1.18

Tenax Therapeutics, Inc. Enters into Amendment to License Agreement with Orion Corporation

Tenax Therapeutics Announces Late-Breaking Clinical Trial Presentation of Phase 2 HELP Study at Heart Failure Society of America (HFSA) Virtual Annual Scientific Meeting

New 90-day high: US$1.63

Price target lowered to US$4.23

Tenax Therapeutics, Inc. announced that it has received $4.735325 million in funding

Tenax Therapeutics, Inc. announced that it expects to receive $4.735325 million in funding

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento